News
DelSiTech and Iveric Bio Enter Exclusive Agreement for Development of Sustained Release Zimura®
Parsippany, N.J. and Turku, Finland – July 6, 2022 – IVERIC…
Destiny Pharma announces start of a new XF-73 research programme
Destiny Pharma announces start of a new XF-73 research programme
Aim…
Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data
Kyowa Kirin expands the license agreement with one new ADC…
eTheRNA: New agreement paves way for development of first African-owned COVID-19 vaccine
A year after the establishment of the mRNA Vaccine Technology…
Versameb to Present during World Continence Week 2022
Lead therapeutic candidate has the potential to treat Stress…
Nordic Bioscience and Roche Diagnostics Strengthen Collaboration for Development of Biomarkers for Chronic Diseases
Nordic Bioscience, a growing biomarker company, today announced…
Biocomposites appoints Group Chief Financial Officer and New UK General Manager
Keele, UK, 15 June 2022 – Biocomposites, an international…
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Top-line data expected from ENHANCE-2 in Q3 2022 and ENHANCE-1…
Synklino completes Series A raise of EUR 29.8 million to advance clinical trials of its drug candidate for the treatment of Cytomegalovirus (CMV)
PKA pension fund lead investment, alongside The Danish Growth…
ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq®)1 to Non-Small Cell Lung Cancer Patients Enrolled in ImaginAb’s iPREDICT Phase IIb Study
Los Angeles, California, USA, June 8th, 2022 – ImaginAb Inc.,…
Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers
Oversubscribed financing co-led by HealthCap and EQT Life Sciences…
Bionical Solutions Bolsters Clinical Services Team
Willington, UK, 7 June 2022 – Bionical Solutions, a leading…
Verona Pharma to Host KOL Event on June 16, 2022
LONDON and RALEIGH, N.C., June 06, 2022 (GLOBE NEWSWIRE) -- Verona…
Destiny Pharma plc – Result of Annual General Meeting and Strategy Update
Brighton, United Kingdom - 27 May 2022 - Destiny Pharma plc…
Destiny Pharma appoints three Non-Executive Directors
Brighton, United Kingdom - 26 May 2022 - Destiny Pharma plc…
ENHANC3D GENOMICS Awarded QuickFire Challenge Grant
Cambridge, UK – 26 May 2022: ENHANC3D GENOMICS (“Enhanc3D”), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Johnson & Johnson Innovation’s Immunology Innovations QuickFire Challenge.
ImaginAb and [Yantai] DongCheng Pharmaceutical Group Sign Exclusive License Agreement to Commercialize CD8 ImmunoPET Agent in China to Serve Pharma and Healthcare Community
Los Angeles, USA and Yantai, China – May 24th, 2022 - ImaginAb,…
Futura Announces Collaboration with Cooper Consumer Health to Commercialise MED3000 in EEA, United Kingdom and Switzerland
Futura Medical plc (AIM: FUM), a pharmaceutical company developing…
Novo Holdings Portfolio Company F2G enters strategic collaboration with Shionogi to commercialise its new antifungal agent Olorofim in Europe and Asia
Deal value includes upfront payment of US$100 million with…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
